Copyright © 2007 The American Society of Human Genetics. All rights reserved.
The American Journal of Human Genetics, Volume 81, Issue 4, 780-791, 1 October 2007
doi:10.1086/521581
Article
Gong-Qing Shena, c, f, Lin Lia, c, f, Domenico Girellii, Sara B. Seidelmanna, c, f, Shaoqi Raoc, f, Chun Fana, c, f, Jeong Euy Parkj, Quansheng Xia, c, f, Jing Lig, Ying Hua, c, f, Oliviero Olivierii, Kandice Marchantd, John Barnarde, Roberto Corrocheri, Robert Elstonh, June Cassanoa, c, f, Susan Hendersona, c, f, Stanley L. Hazenb, Edward F. Plowa, c, f, Eric J. Topol*, k and Qing K. Wang*, a, c, f,
, 
a From the Department of Molecular Cardiology, Case Western Reserve University, Cleveland
b Department of Cell Biology, Case Western Reserve University, Cleveland
c Lerner Research Institute, Center for Cardiovascular Genetics, Department of Cardiovascular Medicine, Case Western Reserve University, Cleveland
d Department of Clinical Pathology, Case Western Reserve University, Cleveland
e Department of Quantitative Health Sciences, Case Western Reserve University, Cleveland
f Cleveland Clinic, Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Case Western Reserve University, Cleveland
g Department of Electrical Engineering and Computer Science, Case Western Reserve University, Cleveland
h Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland
i Department of Clinical and Experimental Medicine, University of Verona, Verona, Italy
j Samsung Medical Center, Sungkyunkwan University, Seoul
k and Scripps Genomic Medicine, The Scripps Research Institute, La Jolla, CA
Address for correspondence and reprints: Dr. Qing K. Wang, Center for Cardiovascular Genetics/NE40, Cleveland Clinic, Cleveland, OH 44195Abstract
Our previous genomewide linkage scan of 428 nuclear families (GeneQuest) identified a significant genetic susceptibility locus for premature myocardial infarction (MI) on chromosome 1p34-36. We analyzed candidate genes in the locus with a population-based association study involving probands with premature coronary artery disease (CAD) and/or MI from the GeneQuest families (381 cases) and 560 controls without stenosis detectable by coronary angiography. A nonconservative substitution, R952Q, in LRP8 was significantly associated with susceptibility to premature CAD and/or MI by use of both population-based and family-based designs. Three additional white populations were used for follow-up replication studies: another independent cohort of CAD- and/or MI-affected families (GeneQuest II: 441 individuals from 22 pedigrees), an Italian cohort with familial MI (248 cases) and 308 Italian controls, and a separate Cleveland GeneBank cohort with sporadic MI (1,231 cases) and 560 controls. The association was significantly replicated in two independent populations with a family history of CAD and/or MI, the GeneQuest II family-based replication cohort and the Italian cohort, but not in the population with sporadic disease. The R952Q variant of LRP8 increased activation of p38 mitogen-activated protein kinase by oxidized low-density lipoprotein. This extensive study, involving multiple independent populations, provides the first evidence that genetic variants in LRP8 may contribute to the development of premature and familial CAD and MI.
| The Ile198Thr and Ala379Val Variants of Plasmatic Paf-Acetylhydrolase Impair Catalytical Activities and Are Associated with Atopy and Asthma The American Journal of Human Genetics, Volume 66, Issue 5, 1 May 2000, Pages 1522-1530 Susanne Kruse, Xiao-Quan Mao, Andrea Heinzmann, Sabine Blattmann, Mark H. Roberts, Sandra Braun, Pei-Song Gao, Johannes Forster, Joachim Kuehr, Julian M. Hopkin, Taro Shirakawa and Klaus A. Deichmann Abstract The platelet-activating factor (PAF) represents a phospholipid with complex biological functions, including involvement in inflammatory processes. The degrading enzyme PAF acetylhydrolase (PAFAH) represents a candidate for asthma and other atopic diseases. Two loss-of-function mutations of PAFAH are associated with severe asthma in Japanese individuals. Our aim was to look for further PAFAH variants in white populations, their possible association with atopic and asthmatic phenotypes, and their functional importance. We picked up three common variants in the PAFAH gene: Arg92His (exon 4), Ile198Thr (exon 7), and Ala379Val (exon 11). The known loss-of-function mutations were not seen. The variant allele Thr198 was found to be highly associated with total IgE concentrations in an atopic population (P=.009) and with “atopic asthma” in an asthmatic population (P=.008). The variant allele Val379 was found to be highly associated with “specific sensitization” in the atopic population (P=.002) and with “asthma” in the asthmatic population (P=.003). By use of recombinant PAFAH enzymes, the variant Val379 showed increased (14 μM) and Thr198 markedly increased (42 μM) KM values compared to the wild type (7 μM); furthermore, Vmax of Val379 was highly increased (132%). Thr198 and Val379 influence plasmatic PAFAH toward lower substrate affinities and therefore are very likely to prolong the activities of PAF. At the same time, they are associated with an increased risk to develop asthma and atopy. Thus, two PAFAH variants seem to play a key role in atopic and asthmatic processes in Caucasian populations. Abstract | | |
| DNA Polymorphisms in Two Paraoxonase Genes (PON1 and PON2) Are Associated with the Risk of Coronary Heart Disease The American Journal of Human Genetics, Volume 62, Issue 1, 1 January 1998, Pages 36-44 Dharambir K. Sanghera, Christopher E. Aston, Nilmani Saha and M. Ilyas Kamboh Abstract Summary:
A common polymorphism at codon 192 in the human paraoxonase (PON) 1 gene has been shown to be associated with increased risk for coronary heart disease (CHD) in Caucasian populations. However, these findings have not been reported consistently in all Caucasian and non-Caucasian populations, suggesting that this is not a functional mutation but may mark a functional mutation present in either PON1 or a nearby gene. Recently, two other PON-like genes, designated “PON2” and “PON3,” have been identified, and they are linked with the known PON1 gene on chromosome 7. Identification of additional polymorphisms in the PON-gene cluster may help to locate the functional polymorphism. In this report, we describe the existence of a common polymorphism at codon 311 (Cys→Ser; PON2*S) in the PON2 gene, as well as its association with CHD alone and in combination with the PON1 codon 192 polymorphism in Asian Indians. The frequency of the PON2*S allele was significantly higher in cases than in controls (.71 vs. .61; P=.016). The age- and sex-adjusted odds ratio (OR) was 2.5 (95% confidence interval [95% CI]=1.8–3.1; P=.0090) for the PON2*S allele carriers. Further stratification of the PON2*S association, on the basis of the presence or absence of the PON1*B allele, showed that the CHD risk associated with the PON2*S allele was confined to PON1*B-allele carriers. Likewise, the PON1*B-allele risk was present only among PON2*S carriers. Age- and sex-adjusted ORs for the PON2*S and PON1*B were 3.6 (95% CI=2.6–4.6; P=.011) and 2.9 (95% CI=2.4–3.5; P=.0002) among the PON1*B and PON2*S carriers, respectively. Our data indicate that both polymorphisms synergistically contribute to the CHD risk in this sample and that this genetic risk is independent of the conventional plasma lipid profile. Abstract | | |